Research Use Only (RUO): All products are sold exclusively for in vitro research. Products must not be used in human or animal trials, administered to humans or animals, or supplied to any third party for human investigational use.
GHRP-6
Tested For:
Purity Weight TFA Free STERILITY ENDOTOXINS(LPS) HEAVY METALS
View Lab Reports
GHRP-6 (Growth Hormone-Releasing Peptide 6) is a synthetic hexapeptide with the amino acid sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, developed by American endocrinologist Cyril Y. Bowers in the early 1980s as the first compound to specifically and dose-dependently stimulate growth hormone release through a mechanism entirely distinct from GHRH. (1,2) GHRP-6 acts as an agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), now known as the ghrelin receptor, and also binds to the CD36 scavenger receptor, conferring additional cardioprotective and cytoprotective properties. (1,2,3) GHRP-6’s discovery was foundational: it directly led to the identification of the GHS receptor in 1996 and subsequently to the discovery of ghrelin, the endogenous hunger hormone, in 1999. (1,2) All subsequent growth hormone secretagogues, including GHRP-2, Hexarelin, and Ipamorelin, were derived from GHRP-6 research. (1) GHRP-6 produces the strongest appetite stimulation of any GHRP, mediated through NPY/AgRP neuron activation in the hypothalamic arcuate nucleus. (4) It is not FDA approved for any therapeutic indication and is prohibited by WADA under S2. (5,6) Available in 5mg and 10mg vials at >99% verified purity.
$19.95 $24.95Price range: $19.95 through $24.95
Peptides are sold as lyophilized (powder) to ensure stability and purity
$19.95 $24.95Price range: $19.95 through $24.95
Buy 1
$19.95
Total:
$19.95
Buy 3 and save 5%
$19.95
$18.95
Total:
Buy 5 and save 10%
$19.95
$17.96
Total:
Buy 10+ and save 15%
$19.95
$16.96
Total:
What is GHRP-6?
GHRP-6 (Growth Hormone-Releasing Peptide 6) is a synthetic hexapeptide with the amino acid sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, developed by American endocrinologist Cyril Y. Bowers in the early 1980s as the first compound to specifically and dose-dependently stimulate growth hormone release through a mechanism entirely distinct from GHRH. (1,2) GHRP-6 acts as an agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), now known as the ghrelin receptor, and also binds to the CD36 scavenger receptor, conferring additional cardioprotective and cytoprotective properties. (1,2,3) GHRP-6’s discovery was foundational: it directly led to the identification of the GHS receptor in 1996 and subsequently to the discovery of ghrelin, the endogenous hunger hormone, in 1999. (1,2) All subsequent growth hormone secretagogues, including GHRP-2, Hexarelin, and Ipamorelin, were derived from GHRP-6 research. (1) GHRP-6 produces the strongest appetite stimulation of any GHRP, mediated through NPY/AgRP neuron activation in the hypothalamic arcuate nucleus. (4) It is not FDA approved for any therapeutic indication and is prohibited by WADA under S2. (5,6) Available in 5mg and 10mg vials at >99% verified purity.
What Is GHRP-6? The Original Growth Hormone Secretagogue
GHRP-6 (Growth Hormone-Releasing Peptide 6, also known as Growth Hormone-Releasing Hexapeptide, developmental code SKF-110679) is a synthetic hexapeptide consisting of six amino acids: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. (1,2) Cyril Y. Bowers developed it at Tulane University through systematic structure-activity relationship studies on met-enkephalin analogs (also spelled analogs) that incorporated unnatural D-amino acids. (1,2) Despite its enkephalin origins, GHRP-6 has no opioid receptor activity. Its biological effects are mediated entirely through growth hormone secretagogue and scavenger receptor pathways. (1,2)
GHRP-6 holds a unique place in the history of peptide research. Characterized (also spelled characterized) in 1984, it was the first synthetic peptide demonstrated to specifically and dose-dependently release growth hormone both in vitro (pituitary cell cultures) and in vivo (animal models and humans) through a receptor pathway completely separate from growth hormone-releasing hormone (GHRH). (1,2) This discovery was pivotal: it proved that a second, independent pathway for GH stimulation existed alongside the GHRH system. The receptor through which GHRP-6 acts was identified in 1996 by Howard et al. as the growth hormone secretagogue receptor (GHSR), and in 1999, Kojima et al. discovered ghrelin as the endogenous ligand for this receptor. (1,2) GHRP-6 literally led to the discovery of ghrelin, one of the most important hormones in metabolism and appetite regulation.
All subsequent growth hormone secretagogues were derived from research on GHRP-6. GHRP-2 was developed as a more potent analog with reduced appetite effects. Hexarelin was developed for enhanced GH-releasing potency with additional cardioprotective properties. Ipamorelin was developed as the most selective GHS with minimal cortisol and prolactin stimulation. (1,4) Understanding GHRP-6 as the parent compound of this entire family provides essential context for researchers comparing these peptides.
GHRP-6 is not FDA-approved for any therapeutic indication. In September 2023, the FDA classified GHRP-6 as a Category 2 bulk drug substance, preventing compounding pharmacies from preparing it for patients. (5) A potential reclassification was announced in February 2026, though no formal FDA policy change had been published as of March 2026. (5) GHRP-6 is prohibited by WADA under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics, at all times. (6) Healius supplies GHRP-6 as a lyophilized (also referred to as lyophilized) powder in 5mg and 10mg vials, intended strictly for laboratory and research applications.
How GHRP-6 Works: The Ghrelin Receptor and Dual Receptor Mechanism
GHRP-6 exerts its effects through two distinct receptor systems, conferring a broader pharmacological profile than that of simple GH stimulation alone. (1,2,3)
The primary mechanism involves agonism at the growth hormone secretagogue receptor 1a (GHS-R1a), now known as the ghrelin receptor. (1,2) GHS-R1a is a G-protein-coupled receptor expressed on somatotroph cells of the anterior pituitary gland and on neurons in the hypothalamic arcuate nucleus. When GHRP-6 binds to GHS-R1a on pituitary somatotrophs, it activates the phosphatidylinositol (PI) second messenger system, leading to protein kinase C (PKC) activation and intracellular calcium mobilization (also spelled mobilization). (7) This signaling cascade is entirely distinct from the cAMP-dependent pathway used by GHRH, which is why GHRP-6 and GHRH produce synergistic GH release when combined: they activate separate intracellular signaling cascades in the same cell. (2,7)
An important physiological detail: GHRP-6 requires endogenous GHRH for its maximal GH-releasing effect. A study by Pandya et al. demonstrated that blocking GHRH with a GHRH antagonist eliminated most of the GH response to GHRP-6, reducing peak GH from 33.8 to 6.2 mcg/L. (8) This means GHRP-6 amplifies the existing GHRH signal rather than operating as a completely independent GH stimulus. This finding provides the pharmacological rationale for combining GHRP-6 with GHRH analogs such as sermorelin or CJC-1295: the GHRH analog provides the primary signal, and GHRP-6 amplifies it via the ghrelin pathway.
The secondary mechanism involves binding to the CD36 scavenger receptor, a multiligand receptor expressed on macrophages, endothelial cells, cardiomyocytes, and adipocytes. (3) CD36 binding activates prosurvival PI-3K/AKT1 pathways, reduces reactive oxygen species (ROS), enhances antioxidant defenses (also spelled defenses), and reduces inflammation. (3) These cytoprotective effects are independent of GH secretion and have been demonstrated in cardiac, neuronal, gastrointestinal, and hepatic cells. (3) The CD36-mediated cardioprotective effects represent one of the most promising and distinctive research avenues for GHRP-6.
GHRP-6 also activates NPY (neuropeptide Y) and AgRP (agouti-related peptide) neurons in the hypothalamic arcuate nucleus via GHS-R1a, producing its characteristic potent appetite-stimulatory effect. (4) This appetite surge begins 20-30 minutes post-injection, lasts approximately 30-60 minutes, and is described as a compelling urge to eat independent of blood glucose levels. (4) This orexigenic effect mimics the pre-meal ghrelin surge that naturally signals hunger.
GHRP-6 Research: GH Release, Cardioprotection, and Wound Healing
GHRP-6 has been studied extensively in both human and animal models, with a research profile that extends well beyond simple GH stimulation. (1,2,3)
Human GH response data come from multiple clinical pharmacology studies. In healthy male volunteers, GHRP-6 at 1 mcg/kg IV bolus produced peak GH levels of approximately 24.4 mcg/L with a delta area under the curve (DAUC) of 1,271 mcg/L/120min. (9) A formal pharmacokinetic study by Fernandez-Perez et al. (2013) in nine healthy male volunteers established a biphasic profile: a rapid distribution phase of approximately 7.6 minutes followed by an elimination phase of approximately 2.5 hours. (4) GHRP-6 also stimulates ACTH and cortisol release, an effect that distinguishes it from more selective GHRPs like Ipamorelin. (9)
The cardioprotective research is particularly extensive, primarily from Cuban research groups led by Berlanga-Acosta. A 2024 study published in Frontiers in Pharmacology demonstrated that GHRP-6 prevented doxorubicin-induced myocardial and extra-myocardial damage in rats by attenuating pro-oxidant activity, enhancing antioxidant reserves, protecting mitochondrial ultrastructure, and upregulating the anti-apoptotic gene Bcl-2. (10) The cytoprotective effects extended beyond the heart to hepatocytes, renal tubular cells, bronchial epithelia, and intestinal enterocytes, suggesting systemic organ-protective properties. (3,10) Earlier work demonstrated that GHRP-6 prevented oxidant cytotoxicity and reduced myocardial necrosis in an acute myocardial infarction model. (3)
Wound-healing research has shown that GHRP-6 accelerated wound closure in rat models, with measurable reductions in wound area within 24 hours of treatment. (4) In full-thickness skin wounds, GHRP-6 enhanced extracellular matrix synthesis, collagen organization (also spelled organization), and angiogenesis through CD36 receptor interactions. In hypertrophic scar models, GHRP-6 reduced exuberant scarring by activating PPARgamma and downregulating pro-inflammatory and pro-fibrogenic cytokine expression. (4)
A Phase I/II clinical trial in 2024 evaluated GHRP-6 in combination with epidermal growth factor (EGF) in patients with acute ischaemic (also spelled ischemic) stroke, reporting improved outcomes. (4) A separate clinical safety study in healthy volunteers demonstrated that GHRP-6 has a broad safety profile with no serious adverse events at standard doses. (3)
GHRP-6 vs GHRP-2: Comparing the Two Primary GHRPs
GHRP-2 was developed as a second-generation refinement of GHRP-6, and understanding the differences between them is essential for protocol design. (1,4)
Both peptides act through the same GHS-R1a receptor and produce potent GH release. GHRP-2 is generally considered slightly more potent in terms of GH release per unit dose, producing higher peak GH levels in comparative studies. (1,4) However, the most clinically relevant difference is their appetite and hormonal side effect profiles.
GHRP-6 produces the strongest appetite stimulation of any GHRP. The orexigenic effect is robust, begins within 20-30 minutes, and is described as a compelling hunger independent of glucose status. (4) GHRP-2 produces notably less appetite stimulation while maintaining strong GH release. (1,4) For researchers where appetite stimulation is undesirable (body composition protocols focused on fat loss), GHRP-2 may be preferred. For researchers in whom appetite stimulation is beneficial (cachexia, wasting conditions, underweight populations, caloric surplus protocols), GHRP-6’s appetite-stimulating effect becomes an advantage.
Both GHRP-6 and GHRP-2 elevate cortisol and prolactin to a greater extent than Ipamorelin does. (1,4) The cortisol elevation is transient and dose-dependent, generally considered clinically insignificant at standard research doses. However, in protocols where cortisol suppression is a priority, Ipamorelin’s selectivity advantage becomes relevant.
GHRP-6 has a stronger evidence base for cardioprotection and cytoprotection through its interactions with the CD36 receptor, with extensive published data on myocardial protection, wound healing, and organ-protective effects. (3,10) GHRP-2 has been studied more in anti-inflammatory contexts, with data showing amelioration of arthritis symptoms and reduced IL-6 levels. (3) Healius offers both GHRP-2 and GHRP-6 for researchers requiring either or both compounds.
GHRP-6 vs Ipamorelin and Hexarelin: The GHS Family
The four primary growth hormone secretagogues form a selectivity spectrum. Understanding where each compound sits on this spectrum helps researchers choose the right tool for their protocol. (1,4)
GHRP-6 is the original, least selective member of the family. It produces potent GH release with significant appetite stimulation, moderate cortisol elevation, and moderate prolactin elevation. Its CD36 binding adds unique cardioprotective properties. (1,3,4) Ipamorelin sits at the opposite end: it is the most selective GHS, producing clean GH release with minimal effects on appetite, cortisol, and prolactin. (4) This makes Ipamorelin the preferred choice for protocols where off-target effects must be minimized (also spelled minimized).
Hexarelin is the most potent GH releaser of the four but also has the most pronounced cortisol and prolactin effects, and shows rapid desensitization (also spelled desensitization) with repeated use. (4) Hexarelin also binds CD36, sharing GHRP-6’s cardioprotective profile but with even stronger cardiac effects in some models. (3)
For researchers designing GH-axis protocols, the practical selection guide is: Ipamorelin for the cleanest GH stimulation with the fewest side effects. GHRP-2 for potent GH release with moderate appetite and hormonal effects. GHRP-6 for potent GH release with strong appetite stimulation and unique cardioprotective properties. Hexarelin for maximum GH release potency with significant hormonal effects and desensitization considerations. Healius offers all four GHS peptides for independent or comparative research.
References
1. Wikipedia. Growth hormone-releasing peptide 6. Hexapeptide SKF-110679, a met-enkephalin analog and GHS-R1a/ghrelin receptor agonist, led to the discovery of GHSR and ghrelin. Updated December 2025.
2. Bowers CY. Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences. 1998;54(12):1316-1329. Original discoverer’s review of the GHRP family.
3. Berlanga-Acosta J, et al. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidence Supporting Their Cytoprotective Effects. PMC5392015. Comprehensive review of GHS-R1a and CD36 dual receptor mechanism, cardioprotective, anti-fibrotic, and organ-protective data.
4. PeptideInsight. GHRP-6 (Growth Hormone Releasing Peptide-6): Research Evidence and Safety Profile. 2026. Appetite mechanism, pharmacokinetics (7.6 min distribution, 2.5 hr elimination), dosing, wound healing, stroke trial.
5. FDA. Category 2 Bulk Drug Substances. September 2023. GHRP-6 is classified as Category 2—potential reclassification announced in February 2026.
6. WADA Prohibited List 2026. Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. GHRPs are prohibited at all times.
7. Adams EF, et al. Growth hormone-releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells. PubMed: 7772238. PI/PKC/Ca2+ signaling cascade, cAMP-independent.
8. Pandya N, et al. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. PubMed: 9543138. The GHRH antagonist blocked most of the GH response to GHRP-6.
9. Pena-Bello L, et al. Effects of ghrelin, GHRP-6, and GHRH on growth hormone, ACTH, and cortisol release in type 1 diabetes mellitus. Metabolism. 2010;59(11):1536-1542. Comparative GH/ACTH/cortisol data.
10. Soto ME, et al. Growth hormone-releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extramyocardial damage by activating prosurvival mechanisms. Frontiers in Pharmacology. 2024; 15:1402138.
Research Use Only Disclaimer
This product is sold strictly for laboratory and research use only. It is not intended for human or animal consumption. It is not a dietary supplement, food, drug, or cosmetic. It is not intended to diagnose, treat, cure, or prevent any disease or condition. The buyer assumes all responsibility for the lawful use of this product in accordance with all applicable local, state, national, and international laws and regulations. By purchasing this product, the buyer confirms that they are a qualified researcher or are purchasing on behalf of a research institution.
Test Conditions
Primary container: Sealed 3 ml flip-top vial Material at assay: Lyophilised powder, solid state Reconstitution: Tested prior to any reconstitution Sampling method: Drawn directly from the vial, sterile technique
GHRP-6 5mg Date Tested: February 2, 2026 Purity (HPLC %): 99.98% Mass of Peptide: GHRP-6 5.9mg TFA Test: Not Detected Endotoxins (LPS): Pass Sterility: Pass Lot #: HP3821208896-5
GHRP-6 10mg Date Tested: February 2, 2026 Purity (HPLC %): 99.99% Mass of Peptide: GHRP-6 6.1mg TFA Test: Not Detected Endotoxins (LPS): Pass Sterility: Pass Lot #: HP3821208896-10
Certificates of Analysis
GHRP-6 5mg Lab Test Report Feb 2026
GHRP-6 10mg Lab Test Report Feb 2026
No. GHRP-6 is not FDA-approved for any therapeutic indication. In September 2023, the FDA classified GHRP-6 as a Category 2 bulk drug substance. (5) A potential reclassification was announced in February 2026 but had not been formally published as of March 2026. GHRP-6 has been used in clinical pharmacology studies and safety trials but has never undergone the full regulatory approval process.
Yes, GHRP-6 is legal to purchase in the United States for in vitro research purposes. It is not classified as a controlled substance. The FDA Category 2 classification prevents compounding pharmacies from preparing it for patients, but does not prohibit the purchase of research-grade GHRP-6 for laboratory use. (5)
Yes, GHRP-6 is legal to purchase in the United Kingdom for in vitro research purposes. The MHRA does not approve it for human therapeutic use, and it is not classified as a controlled substance. For UK delivery information, visit our shipping policy.
Both act through the ghrelin receptor (GHS-R1a) to stimulate GH release. GHRP-2 is slightly more potent per unit dose and produces notably less appetite stimulation. (1,4) GHRP-6 produces the strongest appetite effect of any GHRP, which can be beneficial (cachexia, bulking) or undesirable (fat loss protocols). Both elevate cortisol and prolactin transiently. GHRP-6 has a stronger evidence base for cardioprotection through CD36 receptor interactions. (3) Healius offers both GHRP-2 and GHRP-6.
Ipamorelin is the most selective GHS: it produces clean GH release with minimal appetite stimulation, cortisol elevation, and prolactin elevation. (4) GHRP-6 is less selective: it produces potent GH release with strong appetite stimulation and moderate cortisol/prolactin effects, but adds unique CD36-mediated cardioprotective properties. (1,3) Choose Ipamorelin for the cleanest GH stimulation. Choose GHRP-6 when appetite stimulation is desired or cardioprotective effects are relevant. Healius offers both Ipamorelin and GHRP-6.
Yes, significantly. GHRP-6 produces the strongest appetite stimulation of any growth hormone secretagogue. The effect begins 20-30 minutes after injection, lasts 30-60 minutes, and is characterized by a compelling urge to eat, independent of blood glucose levels. (4) This is mediated through GHS-R1a activation of NPY/AgRP neurons in the hypothalamic arcuate nucleus, the same orexigenic pathway activated by endogenous ghrelin before meals.
Yes, transiently. GHRP-6 stimulates ACTH and cortisol release in a dose-dependent manner. (9) At standard research doses (100-300 mcg), the cortisol elevation is transient and returns to baseline within hours. This is generally considered clinically insignificant for acute use. For protocols where cortisol minimization is critical, Ipamorelin is the preferred alternative because it does not significantly affect cortisol levels. (4)
Yes. GHRP-6 (ghrelin pathway) and CJC-1295 without DAC (GHRH pathway) activate different intracellular signaling cascades, producing synergistic GH release greater than that from either compound alone. (2,7,8) This is one of the most well-established combination protocols in GH-axis research. Typical stacking doses are 100 mcg of each compound administered simultaneously on an empty stomach. Healius offers CJC-1295 no DAC for stacking protocols.
Yes. WADA prohibits GHRP-6 under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. (6) The prohibition applies at all times, both in-competition and out-of-competition. Athletes subject to anti-doping testing must not use GHRP-6.
A formal pharmacokinetic study in nine healthy male volunteers established a biphasic profile: a rapid distribution phase of approximately 7.6 minutes followed by an elimination phase of approximately 2.5 hours. (4) This supports the typical 2-3 times daily dosing protocol used in research.
No. GHRP-6 is a synthetic hexapeptide (six amino acids) that stimulates growth hormone release through the ghrelin receptor. (1,2) It is not a steroid, not an anabolic agent, and does not directly supply growth hormone. It signals the pituitary gland to produce and release its own GH through the endogenous ghrelin pathway.
Yes. GHRP-6 binds to the CD36 scavenger receptor in addition to the ghrelin receptor, activating prosurvival PI-3K/AKT1 pathways. (3) Research has demonstrated cardioprotective effects, including prevention of doxorubicin-induced myocardial damage, reduction of myocardial necrosis in acute MI models, antioxidant defense enhancement, and mitochondrial ultrastructure preservation. (3,10) These effects extend to hepatocytes, renal cells, and other parenchymal organs.
Yes. Food, particularly carbohydrates and fats, blunts the GH response to GHRP-6. Research protocols recommend a minimum of 30 minutes fasting before and 15-20 minutes after administration to maximize the GH response. (4)
Product identity Molecular Weight (g/mol) 873 Peptide Sequence H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 Product Name GHRP-6 Catalogue Number (5mg) G65 Catalogue Number (10mg) G610 Molecular Formula C46H56N12O6 CAS Number 87616-84-0 Peptide Classification Ghrelin receptor agonist, growth hormone secretagogue Lot Number (5mg) HP3821208896-5 Lot Number (10mg) HP3821208896-10 Material profile Active Peptide Compound GHRP-6 peptide Physical Presentation Sterile lyophilised powder, white to ivory in hue Melting Point Decomposes thermally prior to any melting point Analytical verification Mass Spectrum Molecular Weight Observed mass matches theoretical MW (873 g/mol) Amino Acid Composition Profile Residue ratios match the declared peptide sequence Laboratory use and safety Laboratory Handling Advisory Wear laboratory PPE and follow your institutional safety rules. Authorised Application Strictly in vitro research. No clinical, diagnostic, or veterinary application. GHS Hazard Profile Below GHS hazard thresholds at research-scale quantities Storage and handling protocol Recommended Storage, Post-Opening Hold at minus 20 degrees C; limit freeze-thaw cycles Recommended Storage, Sealed Vial Keep at minus 20 degrees C in the sealed vial Sealed Vial Stability 24 months sealed under recommended storage conditions Reconstituted Solution Stability Holds specification for 28 days at 2 to 8 degrees C under sterile handling Reconstitution Guidance Add bacteriostatic or sterile water down the vial wall. Invert gently until dissolved; do not vortex. Laboratory Handling Notes Protect from light. Return to minus 20 degrees C after aliquoting. Maximum 3 freeze-thaw cycles.
GHRP-6
5mg
10mg
$19.95 $24.95Price range: $19.95 through $24.95
Weight
Quantity
from
$49.95
from
$39.95
from
$49.95
from
$79.95
from
$94.95
from
$39.95
from
$109.95
from
$54.95
from
$49.95
from
$59.95
from
$44.95
from
$18.95
from
$44.95
from
$64.95
from
$69.95
from
$59.95
from
$54.95
from
$11.95
from
$49.95
from
$19.95
from
$49.95
from
$39.95
from
$49.95
from
$79.95
from
$94.95
from
$39.95
from
$109.95
from
$54.95
from
$49.95
from
$59.95
from
$44.95
from
$18.95
from
$44.95
from
$64.95
from
$69.95
from
$59.95
from
$54.95
from
$11.95
from
$49.95
from
$19.95
from
$39.95
from
$11.95
from
$49.95
from
$79.95
from
$49.95
from
$59.95
from
$64.95
from
$94.95
from
$18.95
from
$59.95
from
$109.95
from
$94.95
from
$44.95
from
$54.95
from
$49.95
from
$59.95
from
$64.95
from
$19.95
from
$69.95
from
$39.95
from
$39.95
from
$11.95
from
$49.95
from
$79.95
from
$49.95
from
$59.95
from
$64.95
from
$94.95
from
$18.95
from
$59.95
from
$109.95
from
$94.95
from
$44.95
from
$54.95
from
$49.95
from
$59.95
from
$64.95
from
$19.95
from
$69.95
from
$39.95
Join 35,000+ researchers
Subscriber-only pricing, new peptide drops, restock alerts, and fresh lab data delivered before anyone else.